



Pharma & Chemical

Fortnightly Newsletter

15th November to 30th November 2019

Investment and Exit

Investcorp invests Rs 316 Cr in dialysis service provider NephroPlus

25th Nov 2019. Your Stroy

Global alternative asset manager Investcorp announced that it has invested Rs 316 crore (approximately \$45 million) in Hyderabad-based dialysis service provider Nephrocare Health Services Private Limited... [more](#)

Govt plans to invest ₹ 550 crore in HLL Biotech's vaccine facility

26th Nov 2019. Live Mint

India's largest upcoming integrated vaccine complex, which was struggling to start production, would likely get a new lease of life through a fund infusion from the central government... [more](#)

Fund Raising

Zumutor Biologics gets \$4 million in fresh funds

28th Nov 2019. Economics Times

Zumutor Biologics, a biotechnology startup in the immuno-oncology space, has raised \$4 million in fresh funding... [more](#)

Merger and Acquisition

Amar Ujala buys majority stake in PE-backed regional hospital chain Cygnus

25th Nov 2019. VCCircle

Amar Ujala Ltd has acquired a majority stake in a private equity-backed regional hospital chain Cygnus Medicare Pvt. Ltd ... [more](#)

PerkinElmer-owned Tulip Diagnostics to acquire medical devices maker Biosense

20th Nov 2019. VCCircle

Tulip Diagnostics Pvt. Ltd, an in-vitro diagnostic firm, has acquired Mumbai-based Biosense Technologies Pvt. Ltd, a medical devices maker... [more](#)

Advent International to take control of Bharat Serums in fifth India deal this year

18th Nov 2019. VCCircle

Private equity firm Advent International has signed a definitive agreement to acquire a majority stake in biopharmaceutical company Bharat Serums & Vaccines Ltd... [more](#)

Nippon Shokubai, Sanyo Chemical enter merger agreement to form Synfomix

29th Nov 2019. Chemweek

Nippon Shokubai and Sanyo Chemical have entered into an agreement to merge their respective businesses via a share transfer to form an integrated holding company named Synfomix Co. Ltd.... [more](#)

Pharma

Glenmark Pharma gets USFDA nod for diabetes management drug

26th Nov 2019. Economics Times

Glenmark Pharmaceuticals on Tuesday said it has received final nod from the US health regulator for metformin hydrochloride tablets used in the management of type-two diabetes... [more](#)

Zydus Cadila gets USFDA nod for Isosorbide Dinitrate tablets, Desonide Cream

21st Nov 2019. [Economics Times](#)

Drug firm Zydus Cadila on Thursday said it has received approval from the US health regulator to market Isosorbide Dinitrate tablets used to prevent attacks of chest pain... [more](#)

Indian excipient industry to approach DCGI to curb irrational usage of excipients in domestic market

22nd Nov 2019. [Pharma Biz](#)

The Indian excipient industry is planning to approach the Drugs Controller General of India (DCGI) to frame India specific guidelines to curb irrational usage of excipients in the domestic market.... [more](#)

Alembic gets USFDA nod for Silodosin capsules

26th Nov 2019. [ET Health World](#)

Alembic Pharmaceuticals on Tuesday said it has received final approval from the US health regulator for its generic Silodosin capsules used in treatment of benign prostatic hyperplasia.... [more](#)

Roche brings drug for small cell lung cancer to India

22nd Nov 2019. [ET Health World](#)

Drug firm Roche India on Thursday said it has launched Atezolizumab used for the treatment of small cell lung cancer in India after getting nod from Drugs Controller General of India... [more](#)

Zydus Cadila gets USFDA nod for Isosorbide Dinitrate tablets, Desonide Cream

21st Nov 2019. [ET Health World](#)

Drug firm Zydus Cadila on Thursday said it has received approval from the US health regulator to market Isosorbide Dinitrate tablets used to prevent attacks of chest pain... [more](#)

Chemical

Reliance confirms USD9.75-billion investment to build huge oil-to-chemicals complex in India

22nd Nov 2019. [MRCP Last](#)

Reliance Industries has confirmed plans to invest 700 billion Indian rupees (USD9.75 billion) to establish a crude-oil-to-chemicals (COTC) complex ... [more](#)

Government encourages use of Bio-Fertilizers over Chemical Fertilizers

19th Nov 2019. [PIB](#)

Government of India has been encouraging use of bio fertilizers instead of chemical fertilizers through State Governments... [more](#)

Indian Chemical Fertilizer Usage Will Rise To 45 MT by 2025

29th Nov 2019. [Chemin Digest](#)

Consumption of chemical fertilisers in the country will increase to 45 million tonnes by 2025 which will lead to increase in health hazards... [more](#)

Chembid Expands its Activities in the Indian Chemicals Market

28th Nov 2019. [Chemin Digest](#)

Chembid, the world's largest metasearch engine for chemicals and plastics, plans to expand its activities in India in 2020... [more](#)

HealthCare

Greater private sector innovation, digital tools key to quality healthcare services in India at low cost

17th Nov 2019. [Economics Times](#)

Greater private sector innovation and use of technology like digital tools would help India provide quality healthcare services at low cost, billionaire philanthropist and Microsoft co-founder Bill Gates has said, listing priority areas of his foundation for the country... [more](#)

Hospital

India courts private hospitals to boost Modicare

23rd Nov 2019. [Economics Times](#)

India will offer incentives to private hospitals to take part in the government's health insurance programme, potentially the biggest of its kind in the world... [more](#)

Jammu gets first exclusive super speciality cancer hospital

23rd Nov 2019. [ET Energy World](#)

American Oncology Institute (AOI), South Asia's leading chain of cancer hospitals, Saturday extended its services to Jammu and Kashmir... [more](#)

Biotechnology

Biocon, Mylan get USFDA nod for pegfilgrastim drug substance licence

27th Nov 2019. ET Health World

Biotechnology major Biocon on Wednesday said that US health regulator has approved its and Mylan's supplemental biologics licence application for a drug substance to be manufactured at its new facility in Bengaluru... [more](#)

Global News

WuXi Vaccines to invest US\$ 240 mn to build new vaccine manufacturing facility in Ireland

27th Nov 2019. Pharma Biz

WuXi Biologics, a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development, and manufacturing, announced that its subsidiary WuXi Vaccines, engaged in human vaccine Contract Development and Manufacturing... [more](#)

Novartis takes on Sanofi, Amgen with \$9.7 billion takeover of heart drug maker

25th Nov 2019. ET Health World

Swiss drugmaker Novartis is betting on heart drug prospect inclisiran in a \$9.7 billion takeover of The Medicines Co as it challenges cardiovascular medicines from Amgen Inc, Sanofi and Regeneron Pharmaceuticals.... [more](#)

Asahi Kasei to acquire Veloxis Pharmaceuticals for \$1.3bn

27th Nov 2019. Pharmaceutical

Japan-based Asahi Kasei Group has signed an agreement to acquire Danish pharma company Veloxis Pharmaceuticals for DKK8.9bn (\$1.3bn) in an all-cash deal... [more](#)

Mitsubishi Chemical to buy TPU business of AdvanSource Biomaterials

27th Nov 2019. Chemical Technology

Japan-based Mitsubishi Chemical has agreed to acquire US-based AdvanSource Biomaterials' thermoplastic polyurethane elastomer (TPU) business... [more](#)

Best Regards



Monal capital

Believe in values

Dr. Vikas Sadvilkar

Head - Pharma & Healthcare

Monal Capital (P) Limited

Tel.: +91-22-4976 1501 | 4976 1601 | 47081900 Mobile: +91 98210 05733 | [Email: vikas@monalcapital.com](mailto:vikas@monalcapital.com)

114, The Summit business bay, W.E. Highway Metro station, Opp.PVR, Off Andheri Kurla Road, Andheri (E) , Mumbai : 400 093

India, [Website: www.monalcapital.com](http://www.monalcapital.com)

Investment Banking - Debt Syndication | Corporate Finance | Bonds | Equity | Infrastructure | Real Estate | M&A | Stress Asset Solutions | Startup & VC Advisory

Disclaimer: Information gathered & material used in this document is believed to be from reliable sources. Monal Capital however does not warrant the accuracy, reasonableness and/or completeness of any information. Monal Capital and any of its officer's directors, personnel and employees, shall not liable for any loss, damage of any nature, including but not limited to direct, indirect, punitive, special, exemplary, consequential, as also any loss of profit in any way arising from the use of this material in any manner